作者: N. Bellamy , A. Beaulieu , C. Bombardier , J. Esdaile , S. Huang
DOI: 10.1185/03007999209111532
关键词:
摘要: SummaryTwo hundred and ninety-six patients were enrolled in a & month, open-label tolerability study of enteric-coated naproxen with rheumatoid arthritis (n = 1 74) osteoarthritis 122). Thirty percent the greater than 65 years age. Under standard clinical prescribing conditions, 500 mg twice daily 375 mg demonstrated an acceptable profile that was not different from what one would expect naproxen.